Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
In terms of private investments, 2020 was the year of the liquid biopsy.
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.